Evaluation of mucosal adjuvants and immunization routes for the induction of systemic and mucosal humoral immune responses in macaques

References

• Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 2012; 12:592-605; PMID:22828912; http://dx.doi.org/10.1038/nri3251
   PubMed Web of Science ®Google Scholar
• Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006; 6:148-58; PMID:16491139; http://dx.doi.org/10.1038/nri1777
   PubMed Web of Science ®Google Scholar
• Mestecky J, McGhee JR, Michalek SM, Arnold RR, Crago SS, Babb JL. Concept of the local and common mucosal immune response. Adv Exp Med Biol 1978; 107:185-92
   PubMedGoogle Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11:S45-S53; PMID:15812489; http://dx.doi.org/10.1038/nm1213
   PubMed Web of Science ®Google Scholar
• Newsted D, Fallahi F, Golshani A, Azizi A. Advances and challenges in mucosal adjuvant technology. Vaccine 2015; 33:2399-405; PMID:25865473; http://dx.doi.org/10.1016/j.vaccine.2015.03.096
   PubMed Web of Science ®Google Scholar
• Riese P, Sakthivel P, Trittel S, Guzman CA. Intranasal formulations: promising strategy to deliver vaccines. Expert opin Drug Deliv 2014; 11:1619-34; PMID:24962722; http://dx.doi.org/10.1517/17425247.2014.931936
   PubMed Web of Science ®Google Scholar
• Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, Galiza E, Woodrow M, Thierry-Carstensen B, Andersen P, Novicki D, et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PloS one 2009; 4:e6999; PMID:19756141; http://dx.doi.org/10.1371/journal.pone.0006999
   PubMed Web of Science ®Google Scholar
• Buffa V, Klein K, Fischetti L, Shattock RJ. Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice. PloS one 2012; 7:e50529; PMID:23272062; http://dx.doi.org/10.1371/journal.pone.0050529
   PubMedGoogle Scholar
• Van Roey GA, Arias MA, Tregoning JS, Rowe G, Shattock RJ. Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice. Eur J Immunol 2012; 42:353-63; PMID:22057556; http://dx.doi.org/10.1002/eji.201141787
   PubMed Web of Science ®Google Scholar
• Fouda GG, Amos JD, Wilks AB, Pollara J, Ray CA, Chand A, Kunz EL, Liebl BE, Whitaker K, Carville A, et al. Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk. J Virol 2013; 87:6986-99; PMID:23596289; http://dx.doi.org/10.1128/JVI.00528-13
   PubMed Web of Science ®Google Scholar
• Li Y, To J, Verdia-Baguena C, Dossena S, Surya W, Huang M, Paulmichl M, Liu DX, Aguilella VM, Torres J. Inhibition of the human respiratory syncytial virus small hydrophobic protein and structural variations in a bicelle environment. J Virol 2014; 88:11899-914; PMID:25100835; http://dx.doi.org/10.1128/JVI.00839-14
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Fukushima K, Sannan T, Saito N, Takiguchi Y, Sato Y, Hasegawa H, Ishikawa K. Evaluation of the effectiveness and safety of chitosan derivatives as adjuvants for intranasal vaccines. Viral Immunol 2013; 26:133-42; PMID:23509985; http://dx.doi.org/10.1089/vim.2012.0057
   PubMed Web of Science ®Google Scholar
• Vasiliev YM. Chitosan-based vaccine adjuvants: incomplete characterization complicates preclinical and clinical evaluation. Expert Rev Vaccines 2015; 14:37-53; PMID:25262982; http://dx.doi.org/10.1586/14760584.2015.956729
   PubMed Web of Science ®Google Scholar
• McNeela EA, Jabbal-Gill I, Illum L, Pizza M, Rappuoli R, Podda A, Lewis DJ, Mills KH. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 2004; 22:909-14; PMID:15161067; http://dx.doi.org/10.1016/j.vaccine.2003.09.012
   PubMed Web of Science ®Google Scholar
• Huo Z, Sinha R, McNeela EA, Borrow R, Giemza R, Cosgrove C, Heath PT, Mills KH, Rappuoli R, Griffin GE, et al. Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan. Infect Immun 2005; 73:8256-65; PMID:16299322; http://dx.doi.org/10.1128/IAI.73.12.8256-8265.2005
   PubMed Web of Science ®Google Scholar
• Robinson M, Strickland I, Coyle A, Sleeman M, Anderson I, May RM. Thymic Stromal Lymphopoeitin (TSLP) Activates Human And Cynomolgus Macaque Dendritic Cells And Induces Th1 As Well As Th2 Responses In Human Total T Helper Cells. ATS: American Thoracic Society, 2010:A3794-A.
   Google Scholar
• Epaulard O, Adam L, Poux C, Zurawski G, Salabert N, Rosenbaum P, Dereuddre-Bosquet N, Zurawski S, Flamar AL, Oh S, et al. Macrophage- and neutrophil-derived TNF-α instructs skin langerhans cells to prime antiviral immune responses. J Immunol 2014; 193:2416-26; http://dx.doi.org/10.4049/jimmunol.1303339
   PubMed Web of Science ®Google Scholar
• Morse MA, Chapman R, Powderly J, Blackwell K, Keler T, Green J, Riggs R, He LZ, Ramakrishna V, Vitale L, et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res 2011; 17:4844-53; PMID:21632857; http://dx.doi.org/10.1158/1078-0432.CCR-11-0891
   PubMed Web of Science ®Google Scholar
• Clejan S, Mandrea E, Pandrea IV, Dufour J, Japa S, Veazey RS. Immune responses induced by intranasal imiquimod and implications for therapeutics in rhinovirus infections. J Cell Mol Med 2005; 9:457-61; PMID:15963264; http://dx.doi.org/10.1111/j.1582-4934.2005.tb00370.x
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Guyader D, Patton H, Tong MJ, Wright T, McHutchison JG, Meng TC. Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol 2007; 47:174-82; PMID:17532523; http://dx.doi.org/10.1016/j.jhep.2007.02.025
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Brazolot Millan CL, Gramzinski RA, Robinson HL, Santoro JC, Fuller JT, Widera G, Haynes JR, Purcell RH, Davis HL, et al. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med 1999; 5:287-300; PMID:10390545; http://dx.doi.org/10.1007/s0089490050287
   PubMed Web of Science ®Google Scholar
• Xiao P, Patterson LJ, Kuate S, Brocca-Cofano E, Thomas MA, Venzon D, Zhao J, DiPasquale J, Fenizia C, Lee EM, et al. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J Virol 2012; 86:4644-57; PMID:22345466; http://dx.doi.org/10.1128/JVI.06812-11
   PubMed Web of Science ®Google Scholar
• Kraan H, Vrieling H, Czerkinsky C, Jiskoot W, Kersten G, Amorij JP. Buccal and sublingual vaccine delivery. J Control Release 2014; 190:580-92; PMID:24911355; http://dx.doi.org/10.1016/j.jconrel.2014.05.060
   PubMed Web of Science ®Google Scholar
• Larche M. Immune mechanisms of sublingual immunotherapy: are oral Langerhans cells the masters of tolerance? J Allergy Clin Immunol 2010; 126:646-7; PMID:20816196; http://dx.doi.org/10.1016/j.jaci.2010.07.027
   PubMed Web of Science ®Google Scholar
• Huo Z, Bissett SL, Giemza R, Beddows S, Oeser C, Lewis DJ. Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers. PloS One 2012; 7:e33736; PMID:22438987; http://dx.doi.org/10.1371/journal.pone.0033736
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Isakov D, Zhu Q, Dzutsev A, Berzofsky JA. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells. J Immunol 2007; 178:7211-21; http://dx.doi.org/10.4049/jimmunol.178.11.7211
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Hel Z, Kelsall B, Kuznetsov VA, Ahlers JD, Nacsa J, Watkins DI, Allen TM, Sette A, Altman J, et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med 2001; 7:1320-6; PMID:11726972; http://dx.doi.org/10.1038/nm1201-1320
   PubMed Web of Science ®Google Scholar
• Sharpe S, Hanke T, Tinsley-Bown A, Dennis M, Dowall S, McMichael A, Cranage M. Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara. Virology 2003; 313:13-21; PMID:12951017; http://dx.doi.org/10.1016/S0042-6822(03)00282-4
   PubMed Web of Science ®Google Scholar
• Wright PF, Mestecky J, McElrath MJ, Keefer MC, Gorse GJ, Goepfert PA, Moldoveanu Z, Schwartz D, Spearman PW, El Habib R, et al. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. J Infect Dis 2004; 189:1221-31; PMID:15031791; http://dx.doi.org/10.1086/382088
   PubMed Web of Science ®Google Scholar
• Spasova DS, Surh CD. Blowing on embers: commensal microbiota and our immune system. Front Immunol 2014; 5:318; PMID:25120539; http://dx.doi.org/10.3389/fimmu.2014.00318
   PubMed Web of Science ®Google Scholar
• Arias MA, Van Roey GA, Tregoning JS, Moutaftsi M, Coler RN, Windish HP, Reed SG, Carter D, Shattock RJ. Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140. PloS one 2012; 7:e41144; PMID:22829921; http://dx.doi.org/10.1371/journal.pone.0041144
   PubMed Web of Science ®Google Scholar
• Gwinn WM, Johnson BT, Kirwan SM, Sobel AE, Abraham SN, Gunn MD, Staats HF. A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen. Vaccine 2013; 31:1480-9; PMID:23352329; http://dx.doi.org/10.1016/j.vaccine.2013.01.012
   PubMed Web of Science ®Google Scholar
• Ketloy C, Engering A, Srichairatanakul U, Limsalakpetch A, Yongvanitchit K, Pichyangkul S, Ruxrungtham K. Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates. Vet Immunol Immunopathol 2008; 125:18-30; PMID:18571243; http://dx.doi.org/10.1016/j.vetimm.2008.05.001
   PubMed Web of Science ®Google Scholar
• Klein K, Mann JF, Rogers P, Shattock RJ. Polymeric penetration enhancers promote humoral immune responses to mucosal vaccines. J Control Release 2014; 183:43-50; PMID:24657807; http://dx.doi.org/10.1016/j.jconrel.2014.03.018
   PubMed Web of Science ®Google Scholar
• Tregoning JS, Buffa V, Oszmiana A, Klein K, Walters AA, Shattock RJ. A “prime-pull” vaccine strategy has a modest effect on local and systemic antibody responses to HIV gp140 in mice. PloS one 2013; 8:e80559; PMID:24260419; http://dx.doi.org/10.1371/journal.pone.0080559
   PubMedGoogle Scholar
• Lewis DJ, Fraser CA, Mahmoud AN, Wiggins RC, Woodrow M, Cope A, Cai C, Giemza R, Jeffs SA, Manoussaka M, et al. Phase I Randomised Clinical Trial of an HIV-1 CN54, Clade C, Trimeric Envelope Vaccine Candidate Delivered Vaginally. PloS one 2011; 6:e25165; PMID:21984924; http://dx.doi.org/10.1371/journal.pone.0025165
   PubMedGoogle Scholar